DoD Prostate Cancer Laboratory-Clinical Transition Award — Defense Health Agency Contracting Activity - DHACA funding opportunity
Defense Health Agency Contracting Activity - DHACA · Federal agency

DoD Prostate Cancer Laboratory-Clinical Transition Award

The PCRP Laboratory - Clinical Transition Award (LCTA) mechanism was introduced in FY07. Since then, 114 applications have been received, and 13 have been recommended for funding. The Laboratory - Clinical Transition Awa...

95
match
Award $0 Deadline 4252 days ago Location Alabama Type grant Level Federal Closed posted May 30, 2014
✦ AI Summary
  • Who can apply: Federal-level applicants (see eligibility for details).
  • Funding amount: total funding pool ~$4,800,000.
  • Next deadline: October 29, 2014.
  • Issued by: Defense Health Agency Contracting Activity - DHACA.
How was this generated?

The “key facts” mode pulls structured fields directly from the official source posting (amount, deadline, eligibility tags). The AI mode adds a short plain-English narrative on top, generated from the same source. Always verify with the agency before applying.

AI-generated. Always verify with the official source.

Award amount
$0
Deadline
4252 days ago
Oct 29, 2014
Total pool
$4.8M

About this opportunity

The PCRP Laboratory - Clinical Transition Award (LCTA) mechanism was introduced in FY07. Since then, 114 applications have been received, and 13 have been recommended for funding. The Laboratory - Clinical Transition Award supports product-driven preclinical studies of promising lead agents or medical devices that have the potential to revolutionize prostate cancer clinical care. Lead Agents: It is anticipated that lead agent development projects supported by this award will focus on generating pharmacology and toxicology data in preclinical studies for inclusion in a Food and Drug Administration (FDA) Investigational New Drug (IND) application and/or establishing agent production according to current Good Manufacturing Practice (cGMP). Applicants are expected to have a validated target and to have identified one lead agent (or a limited number of lead agents for optimization) before applying for this award. In addition, the PI should present data establishing the lead agent’s mechanism of action and demonstrating (including sensitivity and specificity), and target availability and distribution in relevant human tissues. In addition, the inclusion of substantive information from model systems that supports the potential efficacy of the lead agent in humans is highly recommended. Lead agents are defined as novel biological and molecular or chemical therapeutic or imaging agents having potential clinical application to prostate cancer. Examples of lead agents include, but are not limited to, novel contrast agents, and others. Medical Devices: Medical device projects to be supported by this award will test medical devices in preclinical studies with the intent of achieving an FDA Investigational Device Exemption (IDE) application and/or cGMP production of the medical device. As appropriate, the PI should present preliminary data demonstrating effectiveness (including sensitivity and specificity) for the medical device, as well as target availability and distribution in relevant human tissues. In addition, the inclusion of substantive information from model systems that supports the potential efficacy of medical device in humans is highly recommended. Examples of medical devices include, but are not limited to, diagnostic or prognostic tests ( microfluidic device, genomic and genetic microarray devices), imaging devices, and other medical technology. Lead agents or medical devices supported by this award are expected to have high potential for commercial licensing for continued development and clinical use. The PI must provide a transition plan (including potential funding and resources) to describe how the product will progress to the next phase of development ( clinical trials and/or delivery to market) after the completion of the PCRP award. The PCRP strongly encourages investigators to leverage existing resources with commercial partners to increase potential gains in translating preclinical research outcomes for continued development and clinical application. Applications that demonstrate cost-sharing with commercial partners are particularly encouraged. The National Cancer Institute has constructed developmental pathways for translational research that may be useful for designing translational research studies for support under the LCTA mechanism. These pathways are comprehensive and span the entire translational research continuum from discovery of a target to clinical trials (http://www.cancer.gov/PublishedContent/Files/images/trwg/agents_oct08.pdf). PIs applying to the LCTA are expected to address at least one of the PCRP focus areas and are highly encouraged to address one of the PCRP overarching challenges. If the proposed project does not address any of the overarching challenges, the application should include a description to justify how the project will nevertheless address a critical need in the field of prostate cancer research and/or patient care.

Funding agency

Tags

Want help applying?

Our specialists will check your eligibility, prepare the application, and walk you through every step — for free. Create a free account →

Who can apply

Eligibility details aren't on file yet — check the agency source link in the Documents tab for the latest rules.

Geographic eligibility

  • Alabama
  • Alaska
  • Arizona
  • Arkansas
  • California
  • Colorado
  • Connecticut
  • Delaware
  • Florida
  • Georgia
  • Hawaii
  • Idaho
  • Illinois
  • Indiana
  • Iowa
  • Kansas
  • Kentucky
  • Louisiana
  • Maine
  • Maryland
  • Massachusetts
  • Michigan
  • Minnesota
  • Mississippi
  • Missouri
  • Montana
  • Nebraska
  • Nevada
  • New Hampshire
  • New Jersey
  • New Mexico
  • New York
  • North Carolina
  • North Dakota
  • Ohio
  • Oklahoma
  • Oregon
  • Pennsylvania
  • Rhode Island
  • South Carolina
  • South Dakota
  • Tennessee
  • Texas
  • Utah
  • Vermont
  • Virginia
  • Washington
  • West Virginia
  • Wisconsin
  • Wyoming
  • District of Columbia

How to apply

We don't have application instructions on file yet — head straight to the official source.

Apply on agency site
Tip from our team:

Read the agency's eligibility checklist before you start — it's almost always shorter than the full NOFO and will tell you in 90 seconds whether to keep going.

Need help getting in touch with the right agency contact?

Create a free account and our specialists will guide you through the application end-to-end.

Source documents

View on agency site
Canonical NOFO, application packet, and forms
No supplemental documents yet.

Direct downloads (NOFO PDFs, application forms, FAQs) will appear here once our team attaches them. For now, the agency site has the canonical packet.

Citation details

Source systemgrants.gov
Source ID256296
PostedMay 30, 2014

Frequently asked questions

No FAQs yet.

Have a question about this fund? Sign in to open a ticket about this fund.